FDA to clarify rules on advisory committee members

BMJ 2006; 333 doi: 10.1136/bmj.333.7562.278 (Published 3 August 2006)
Cite this as: BMJ 2006;333:278.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    The US Food and Drug Administration announced last week that it is to develop guidelines to clarify the relationships between members of its advisory committees and pharmaceutical companies. The aim is to make advisory committee processes more effective and to reassure the public about the integrity of the process.

    There will be a period for public comment on the proposed new rules.

    Some scientists with industry ties are granted waivers to allow them to participate in advisory committees, but the process is unclear.

    The advisory committees provide expert advice and recommend …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL